Blood-laboratory materials and testing costs rose $16.8 million in the three months ended June 30. That is the detail inside Caris Life Sciences' headline: revenue climbed 45.4% from the comparable period a year earlier, to $263.7 million.

Operating income went from a $18.0 million loss to $26.9 million of income, taking operating margin from negative 9.9% to 10.2%. Net income was still slightly negative at $637,000, but that was a long way from the $71.8 million loss recorded in the comparable three months.

Caris attributes the sales growth to more clinical cases, higher reimbursement, and improved average selling prices from enhanced contracting.

"The increase was driven primarily by higher clinical case volume and higher reimbursement, including improved average selling prices resulting from enhanced contracting."

10-Q 2026-08-05; revenue, clinical regulatory

The explanation matters because this was not just a cost-cutting quarter. Caris says more testing activity and better reimbursement powered the top line, while research and development spending rose 29.2% to $32.4 million. The company spent more on the business and still produced positive operating income.

Gross profit expanded faster than revenue, rising 58.0% to $179.6 million. Caris tied that increase primarily to molecular profiling services revenue.

"Gross Profit Gross profit, calculated as total revenue less cost of services, was $179.6 million for the three months ended June 30, 2026, compared to $113.7 million for the three months ended June 30, 2025, an increase of $65.9 million, or 58.0%, primarily due to the increase in molecular profiling services revenue."

10-Q 2026-08-05; revenue, margin

That is the operating leverage in the filing: gross profit grew faster than sales, and operating expenses did not grow as quickly. Stock compensation also fell 21.5% to $22.2 million, partly because the prior-year period included awards tied to the IPO-related vesting condition.

The balance-sheet and ownership details add context to the results. Accounts receivable rose 129.7%, nearly three times the pace of revenue growth. Capital expenditures increased 695.5%, while free-cash-flow margin reached 6.0%. Those are observations, not explanations: Caris does not disclose in the supplied receipts why receivables and capex moved so sharply.

The denominator changed even more dramatically. Diluted shares rose from 64.9 million to 282.9 million, a 335.8% increase. That makes the move in diluted EPS from negative 7.97 to 0.00 less informative than the operating-income swing, because the per-share calculation now spreads results across a much larger share base.

Caris' annual results show the improvement did not begin this morning. Revenue reached $812.0 million in 2025, with operating margin at 5.6%, after much deeper losses in 2023 and 2024. At the latest close, the stock was $16.50, while the company carried $417.5 million of net cash and an enterprise value of $2.3 billion.

The next quarterly report's cash-flow statement, accounts-receivable balance, capital spending, and diluted share count will clarify whether the operating-income improvement is accompanied by comparable cash conversion and a stable denominator.

Caris is growing faster, earning more on each dollar of revenue, and counting many more shares than it did a year ago.